Cargando…

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats

rHuEPO plays a central role as chemicals for the treatment of many diseases. Due to its short half-life, the main aim for this pharmacokinetic study is to investigate a newly developed PEG-rHuEPO with large molecular weight in SD rats. After a single intramuscular administration of different doses o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Xiaohan, Chen, Zhiyong, Yu, Zhuoran, Ge, Yonghong, Zeng, Xianyin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913096/ https://www.ncbi.nlm.nih.gov/pubmed/24575314 http://dx.doi.org/10.1155/2014/918686

Ejemplares similares

Expression of adrenomedullin in rats after spinal cord injury and intervention effect of recombinant human erythropoietin
por: Zhao, Liang, et al.
Publicado: (2016)

Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015)

Effects of Recombinant Human Erythropoietin on Revascularization of Full Thickness Skin Grafts in Rat
por: Fatemi, Mohammad Javad, et al.
Publicado: (2014)

The Clinical Impact of Recombinant Human Erythropoietin
por: Muirhead, N
Publicado: (1997)

Research in the precaution of recombinant human erythropoietin to steroid-induced osteonecrosis of the rat femoral head
por: Jiang, Lu-yong, et al.
Publicado: (2017)

Recombinant Erythropoietin in Humans Has a Prolonged Effect on Circulating Erythropoietin Isoform Distribution
por: Aachmann-Andersen, Niels Jacob, et al.
Publicado: (2014)

Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats
por: Soni, Hitesh M., et al.
Publicado: (2014)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

Ameliorative Effect of Recombinant Human Erythropoietin and Ischemic Preconditioning on Renal Ischemia Reperfusion Injury in Rats
por: Elshiekh, Mohammed, et al.
Publicado: (2015)

Modified recombinant human erythropoietin with potentially reduced immunogenicity
por: Susantad, Thanutsorn, et al.
Publicado: (2021)

Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin
por: Cohan, Reza Ahangari, et al.
Publicado: (2011)

Recombinant human erythropoietin for treating severe traumatic brain injury
por: Bai, Xiao-Fei, et al.
Publicado: (2018)

Preoperative recombinant human erythropoietin in anemic surgical patients
por: Monk, Terri G
Publicado: (2004)

Recombinant human erythropoietin therapy in critically ill patients
por: Georgopoulos, D, et al.
Publicado: (2005)

Human recombinant erythropoietin improves motor function in rats with spinal cord compression-induced cervical myelopathy
por: Tanaka, Takahiro, et al.
Publicado: (2019)

Modified aptamers as reagents to characterize recombinant human erythropoietin products
por: Jankowski, Wojciech, et al.
Publicado: (2020)

Cross-platform transcriptomic profiling of the response to recombinant human erythropoietin
por: Wang, Guan, et al.
Publicado: (2021)

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
por: Barosi, G., et al.
Publicado: (1998)

Trends in Use, Cost, and Outcomes of Human Recombinant Erythropoietin, 1989-98
por: Greer, Joel W., et al.
Publicado: (1999)

Cytoprotective Effect of Recombinant Human Erythropoietin Produced in Transgenic Tobacco Plants
por: Kittur, Farooqahmed S., et al.
Publicado: (2013)

Recombinant human erythropoietin improves neurological outcomes in very preterm infants
por: Song, Juan, et al.
Publicado: (2016)

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1
por: Sherstoboev, E. Yu., et al.
Publicado: (2022)

Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood–brain barrier in rats
por: Rip, Jaap, et al.
Publicado: (2014)

Expression of Bcl-2 and Bad in hippocampus of status epileptic rats and molecular mechanism of intervened recombinant human erythropoietin
por: Yu, Jianghua, et al.
Publicado: (2018)

Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia
por: Garrido, Patrícia, et al.
Publicado: (2015)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
por: Yuan, Jiani, et al.
Publicado: (2017)

Transcriptomic Markers of Recombinant Human Erythropoietin Micro-Dosing in Thoroughbred Horses
por: Dahlgren, Anna R., et al.
Publicado: (2021)

The Recombinant Human Erythropoietin Administered in Neonatal Rats After Excitotoxic Damage Induces Molecular Changes in the Hippocampus
por: Rivera-Cervantes, Martha Catalina, et al.
Publicado: (2019)

Effect of Zinc Supplementation on Renal Anemia in 5/6-Nephrectomized Rats and a Comparison with Treatment with Recombinant Human Erythropoietin
por: Feng, Hui-Lin, et al.
Publicado: (2019)

Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro—In Vivo Correlation
por: Dubaj, Tibor, et al.
Publicado: (2022)

Pharmacokinetics, Biodistribution, and Biosafety of PEGylated Gold Nanoparticles In Vivo
por: Kozics, Katarina, et al.
Publicado: (2021)

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats
por: Espinoza, Yero, et al.
Publicado: (2019)

Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
por: Shi, Yanan, et al.
Publicado: (2012)

Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat
por: Teixeira, M., et al.
Publicado: (2012)

The neuroprotective effect of recombinant human erythropoietin via an antiapoptotic mechanism on hypoxic-ischemic brain injury in neonatal rats
por: Kim, Moon Sun, et al.
Publicado: (2010)

Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated β-elemene liposomes
por: Zhai, Bingtao, et al.
Publicado: (2020)

The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency
por: Liang, Yan, et al.
Publicado: (2022)

The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.
por: Joiner, B., et al.
Publicado: (1993)

Trends in the Treatment of Anemia Using Recombinant Human Erythropoietin in Patients with HIV Infection
por: Sullivan, Patrick S, et al.
Publicado: (2011)

A gene responsible for prolyl-hydroxylation of moss-produced recombinant human erythropoietin
por: Parsons, Juliana, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p1q70eqsrjot9kh5l1at6qi69f